Elizabeth Sokol
Overview
Explore the profile of Elizabeth Sokol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sokol E, LaBarre B, Pinto N, Kreissman S, Granger M, Park J, et al.
EJC Paediatr Oncol
. 2025 Jan;
4.
PMID: 39822770
Background: Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those achieving a complete response (CR) having superior outcomes. Methods: We evaluated...
2.
Lebowitz J, Porto A, Clarke C, Sokol E, Fortunato J
J Adolesc Health
. 2024 Sep;
75(6):985-987.
PMID: 39243261
No abstract available.
3.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, et al.
J Natl Compr Canc Netw
. 2024 Aug;
22(6):413-433.
PMID: 39151455
Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of...
4.
Applebaum M, Ramesh S, Dyer E, Pomaville M, Doytcheva K, Dolezal J, et al.
Res Sq
. 2024 Jun;
PMID: 38883758
A deep learning model using attention-based multiple instance learning (aMIL) and self-supervised learning (SSL) was developed to perform pathologic classification of neuroblastic tumors and assess -amplification status using H&E-stained whole...
5.
Patel K, McQuaid S, Ketterl T, Benedetti D, Sokol E
Pediatr Blood Cancer
. 2024 Apr;
71(7):e31010.
PMID: 38637906
No abstract available.
6.
Desai A, Applebaum M, Karrison T, Oppong A, Yuan C, Berg K, et al.
Cancer
. 2022 Jun;
128(15):2967-2977.
PMID: 35665495
Background: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors...
7.
Lemoine C, Lust H, Sokol E, Chou P, Superina R
Pediatr Blood Cancer
. 2021 Dec;
69(4):e29538.
PMID: 34957675
No abstract available.
8.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol
. 2020 Sep;
38(31):3720-3721.
PMID: 32931402
No abstract available.
9.
Sokol E, Desai A, Applebaum M, Valteau-Couanet D, Park J, Pearson A, et al.
J Clin Oncol
. 2020 Apr;
38(17):1906-1918.
PMID: 32315273
Purpose: The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked...
10.
Sokol E, Desai A
Children (Basel)
. 2019 Feb;
6(2).
PMID: 30754710
Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are risk-stratified using a number of features including age at diagnosis, disease stage, tumor histology, status (amplified versus...